Bioexotec
Bioexotec develops blood or saliva-based cancer diagnostics technology by performing smart analysis of extracellular vesicles.
Classification
Profile
Funding
Funding details not yet available.
Non-invasive cancer diagnostics using smart analysis of extracellular vesicles found in blood or saliva.
laboratories, hospitals, cancer research institutions
Per-test fee - Charged to hospitals/diagnostic labs (e.g., €150-€250 per assay) · Subscription/volume contracts - Fixed annual fees based on projected test volumes, smoothing cash flow · Licensing of IP - Potential royalty income from third-party labs that adopt the exosome signature under a licensing deal
Direct sales force - Dedicated scientific-sales reps targeting hospital labs and oncology networks · Strategic distribution partners - Established diagnostic distributors (e.g., Roche Diagnostics, Siemens Healthineers) to reach a broader Eur · Clinical trial collaborations - Partnerships with university hospitals (TU Munich, LMU) that act as early
Technical University of Munich (TUM) via IDEAward participation
R&D, intellectual property development
Proprietary technology for EV analysis and leadership by Prof. Dr. Marie-Nicole Theodorakis.
Developing smart analysis technology for extracellular vesicles to enable blood or saliva-based cancer diagnostics.
High-touch scientific support - Dedicated clinical liaison scientists to assist with assay integration, validation, and interpretation · Training & certification programs - On-site and virtual workshops for lab technicians and physicians · Subscription-style service contracts - Annual test-volume agreements with volume discounts and guaranteed supp
Competes in the liquid biopsy and non-invasive cancer diagnostics space; differentiates through specific focus on smart analysis of extracellular vesicles for tumor signatures.
Need for non-invasive cancer detection methods utilizing biological information from extracellular vesicles.
Diversify revenue - Add licensing and SaaS analytics to reduce reliance on per-test fees · Strengthen distribution - Formalize agreements with established diagnostic distributors for rapid scale · Enhance payer narrative - Publish health-economics models quantifying cost avoidance from early detection
Value Proposition ↔ Customer Segments - Early-stage detection directly addresses the pain point of costly late-stage treatment for hospitals · Channels ↔ Key Partnerships - Distribution partners amplify the reach of the direct-sales channel, especially in markets lacking a local sal · Revenue Streams ↔ Cost Structure - Subscription contracts help o
Patented technology & clinical validation - The company holds a proprietary exosomal signature and has completed a first-in-human saliva stu · Regulatory traction - Ongoing CE-mark preparation and two-year regulatory navigation experience demonstrate realistic market-entry timelines · Strong academic backing - Founders are senior clinicians/scienti
No investors recorded yet.